{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:08:32Z","timestamp":1784610512135,"version":"3.55.0"},"reference-count":37,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kidney Research UK"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic kidney disease (CKD) represents a state of oxidative stress imbalance, which is potentially amplified by iron deficiency. Intravenous iron is considered safe and efficacious in the treatment of iron deficiency anemia, however, concerns remain regarding its potential pro-oxidant effect, leading to inflammatory and endothelial consequences. This pooled analysis of two pilot randomized controlled trials aimed to group and analyze the potential effect of high-dose intravenous iron (ferric derisomaltose, 1000 mg) on markers of oxidative stress (thiobarbituric acid reactive substance), inflammation (C-reactive protein, interleukins 6 and 10) and endothelial response (E-selectin, P-selectin) in patients with non-dialysis-dependent CKD and iron deficiency with\/without anemia. Pulse wave velocity as a surrogate measure of arterial stiffness was measured. Thirty-six patients were included. No statistically significant trend was identified for any of the aforementioned markers. Stratification and comparison of data based on CKD stage did not yield statistically significant trajectories with the exception of the C-reactive protein in CKD stage 3b. These results suggest that high-dose intravenous iron does not impact measures of oxidative stress or inflammation; however, the results are not conclusive. Further research in a larger cohort is necessary to characterize the effect of intravenous iron on oxidative status and inflammation and its potential sequela in CKD.<\/jats:p>","DOI":"10.3390\/ijms232416016","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T03:55:39Z","timestamp":1671162939000},"page":"16016","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Markers of Oxidative Stress, Inflammation and Endothelial Function following High-Dose Intravenous Iron in Patients with Non-Dialysis-Dependent Chronic Kidney Disease\u2014A Pooled Analysis"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1452-7757","authenticated-orcid":false,"given":"Xenophon","family":"Kassianides","sequence":"first","affiliation":[{"name":"Academic Renal Research, Hull University Teaching Hospitals NHS Trust and the Hull York Medical School, Kingston upon Hull HU3 2JZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"White","sequence":"additional","affiliation":[{"name":"School of Physician Associate Studies, Hull York Medical School, Kingston upon Hull HU6 7RU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-9622","authenticated-orcid":false,"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Academic Renal Research, Hull University Teaching Hospitals NHS Trust and the Hull York Medical School, Kingston upon Hull HU3 2JZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: An update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00467-018-4005-4","article-title":"Oxidative stress in chronic kidney disease","volume":"34","author":"Daenen","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s41100-018-0195-2","article-title":"Oxidative stress in chronic kidney disease","volume":"4","author":"Ling","year":"2018","journal-title":"Ren. Replace. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/ndt\/16.9.1863","article-title":"Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters","volume":"16","author":"Schiffl","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1525-1594.1995.tb02431.x","article-title":"Hemodialysis with Cellulose Membranes Primes the Neutrophil Oxidative Burst","volume":"19","author":"Ward","year":"1995","journal-title":"Artif. Organs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1073\/pnas.261708798","article-title":"Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats","volume":"99","author":"Walter","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s12603-009-0195-6","article-title":"Oxidative stress in older patients with iron deficiency anaemia","volume":"13","author":"Baccin","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bhandari, S., Pereira, D.I.A., Chappell, H.F., and Drakesmith, H. (2018). Intravenous Irons: From Basic Science to Clinical Practice. Pharmaceuticals, 11.","DOI":"10.3390\/ph11030082"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14740338.2021.1853098","article-title":"Improving the safety of intravenous iron treatments for patients with chronic kidney disease","volume":"20","author":"Kassianides","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/ckj\/sfaa212","article-title":"Intravenous iron therapy and the cardiovascular system: Risks and benefits","volume":"14","author":"Ekart","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/08860220802599106","article-title":"Lipid Peroxidation Products Formation with Various Intravenous Iron Preparations in Chronic Kidney Disease","volume":"31","author":"Ganguli","year":"2009","journal-title":"Ren. Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.52586\/4958","article-title":"Impact of intravenous iron on cardiac and skeletal oxidative stress and cardiac mitochondrial function in experimental uraemia chronic kidney disease","volume":"26","author":"Bhandari","year":"2021","journal-title":"Front. Biosci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bhandari, S., Allgar, V., Lamplugh, A., Macdougall, I., and Kalra, P.A. (2021). A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02308-y"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.23876\/j.krcp.20.120","article-title":"The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: A randomized controlled pilot study","volume":"40","author":"Kassianides","year":"2021","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer\u00ae), a new intravenous iron preparation and its clinical implications","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1093\/ndt\/gfr711","article-title":"Effects of intravenous iron on mononuclear cells during the haemodialysis session","volume":"27","author":"Merino","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000107928","article-title":"Slow Intravenous Iron Administration Does Not Aggravate Oxidative Stress and Inflammatory Biomarkers during Hemodialysis: A Comparative Study between Iron Sucrose and Iron Dextran","volume":"27","author":"Malindretos","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"De Souza, L.V., Hoffmann, A., Fischer, C., Petzer, V., Asshoff, M., Theurl, I., Tymoszuk, P., Seifert, M., Brigo, N., and Hilbe, R. (2022). Comparative analysis of oral and intravenous iron therapy in rat models of inflammatory anemia and iron deficiency. Haematologica, Online ahead of print.","DOI":"10.3324\/haematol.2022.281149"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.jrn.2017.12.009","article-title":"Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis\u2014Effect on Fibroblast Growth Factor-23 Metabolism","volume":"28","author":"Fukao","year":"2018","journal-title":"J. Ren. Nutr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1681\/ASN.2013080838","article-title":"Iron Sucrose Accelerates Early Atherogenesis by Increasing Superoxide Production and Upregulating Adhesion Molecules in CKD","volume":"25","author":"Kuo","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000035250.66458.67","article-title":"Iron Therapy, Advanced Oxidation Protein Products, and Carotid Artery Intima-Media Thickness in End-Stage Renal Disease","volume":"106","author":"Massy","year":"2002","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/MIB.0b013e318281f4db","article-title":"Iron Deficiency Generates Secondary Thrombocytosis and Platelet Activation in IBD: The Randomized, Controlled ThromboVIT Trial","volume":"19","author":"Schmid","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e12692","DOI":"10.1002\/rth2.12692","article-title":"Platelet reactivity and platelet count in women with iron deficiency treated with intravenous iron","volume":"6","author":"Elstrott","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1681\/ASN.2020101440","article-title":"Platelet Function in CKD: A Systematic Review and Meta-Analysis","volume":"32","author":"Baaten","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"van Bladel, E.R., de Jager, R.L., Walter, D., Cornelissen, L., Gaillard, C.A., Boven, L.A., Roest, M., and Fijnheer, R. (2012). Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro. BMC Nephrol., 13.","DOI":"10.1186\/1471-2369-13-127"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mikhail, A., Brown, C., Williams, J.A., Mathrani, V., Shrivastava, R., Evans, J., Isaac, H., and Bhandari, S. (2017). Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0688-1"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kalra, P.A., Bhandari, S., Spyridon, M., Davison, R., Lawman, S., Mikhail, A., Reaich, D., Pritchard, N., McCafferty, K., and Moore, J. (2020). NIMO-CKD-UK: A real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrol., 21.","DOI":"10.1186\/s12882-020-02180-2"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous Iron in Patients Undergoing Maintenance Hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: The FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2020-11-3","article-title":"Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: A narrative review","volume":"10","author":"Kassianides","year":"2021","journal-title":"Drugs Context"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/CCM.0000000000001420","article-title":"Does IV Iron Induce Plasma Oxidative Stress in Critically Ill Patients? A Comparison With Healthy Volunteers","volume":"44","author":"Lasocki","year":"2016","journal-title":"Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Peir\u00f3, M., Mart\u00edn-Ontiyuelo, C., Rod\u00f3-Pi, A., Piccari, L., Admetll\u00f3, M., Dur\u00e1n, X., Rodr\u00edguez-Chiarad\u00eda, D.A., and Barreiro, E. (2021). Iron Replacement and Redox Balance in Non-Anemic and Mildly Anemic Iron Deficiency COPD Patients: Insights from a Clinical Trial. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091191"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1159\/000507872","article-title":"Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease","volume":"51","author":"Bhandari","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13063-019-3291-x","article-title":"Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)","volume":"20","author":"Ziedan","year":"2019","journal-title":"Trials"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wang, N. (2014). Cell Adhesion Molecules (CAMs). Encycl. Neurol. Sci., 628\u2013629.","DOI":"10.1016\/B978-0-12-385157-4.00053-1"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/24\/16016\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:42:31Z","timestamp":1760146951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/24\/16016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":37,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ijms232416016"],"URL":"https:\/\/doi.org\/10.3390\/ijms232416016","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]}}}